Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Susan Danto

Child & Adolescent Psychiatry Albuquerque, NM Medical Doctor

NPI 1669529210 CMS profile 381939

7801 Academy Ne, Bldg. 1, Suite 202, Albuquerque, NM 87109

Open in the dashboard

General payments

$2,750

139 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Susan Danto of Albuquerque, NM is reported in the CMS Open Payments database as having received $2,750 across 139 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 88th percentile of Child & Adolescent Psychiatry profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $121 1
2023 General $33 1
2022 General $890 45
2021 General $222 12
2020 General $291 17
2019 General $1,194 63

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Susan Danto
  • Child & Adolescent Psychiatry median
  • Middle half of Child & Adolescent Psychiatry
  • National median

In program year 2025, general payments to Susan Danto were reported at $121. Among 1,601 Child & Adolescent Psychiatry profiles paid that year, the median was $132 and the middle half received between $41 and $474.

Show as a table
Year Susan Danto Child & Adolescent Psychiatry median Middle half National median
2019 $1,194 $129 $42–$419 $163
2020 $291 $81 $28–$226 $114
2021 $222 $115 $31–$326 $132
2022 $890 $124 $40–$382 $149
2023 $33 $130 $45–$420 $160
2024 $0 $141 $42–$490 $164
2025 $121 $132 $41–$474 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Sunovion Pharmaceuticals Inc. $1,922 101 payments
  2. Otsuka America Pharmaceutical, Inc. $356 22 payments
  3. Teva Pharmaceuticals USA, Inc. $267 9 payments
  4. Alkermes, Inc. $134 2 payments
  5. Takeda Pharmaceuticals U.S.A., Inc. $27 3 payments
  6. Lundbeck LLC $23 1 payment
  7. Neurocrine Biosciences, Inc. $20 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $2,750 139 payments
Products named General payments · program years 2019–2025
  1. LATUDA $1,922 101 payments
  2. REXULTI $298 18 payments
  3. AUSTEDO $267 9 payments
  4. ARISTADA INITIO $121 1 payment
  5. ARISTADA Cns $121 1 payment
  6. ARISTADA Cns $121 1 payment
  7. ARISTADA Cns $121 1 payment
  8. ARISTADA Cns $121 1 payment
  9. ABILIFY MAINTENA $86 6 payments
  10. BRINTELLIX $23 1 payment
  11. Other $98 8 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 18 drugs

Part D claims

322

Median for Neuropsychiatry: 88

Drug cost

$11,892

Median for Neuropsychiatry: $2,689

Branded share of claims

29.8%

Median for Neuropsychiatry: 16.7%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Adderall Xr Dextroamphetamine/Amphetamine Brand 12 $2,524
Divalproex Sodium Generic 13 $1,619
Methylphenidate Er Methylphenidate Hcl Brand 12 $1,444
Aripiprazole Generic 33 $1,372
Naltrexone Hcl Generic 12 $998
Bupropion Xl Bupropion Hcl Brand 22 $536
Dextroamphetamine-Amphetamine Dextroamphetamine/Amphetamine Brand 11 $485
Fluoxetine Hcl Generic 25 $442
Venlafaxine Hcl Er Venlafaxine Hcl Brand 13 $388
Lamotrigine Generic 30 $380

The 10 drugs with the highest cost, of 18 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 1,891 Part D prescribers listed as Neuropsychiatry; they describe a distribution and say nothing about conduct.

Records

139 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Child & Adolescent Psychiatry in New Mexico

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record